Discussion  by unknown
naires also did not allow for further investigation of the
impact of immunomodulating medications on disease or
on physical and mental QoL.
CONCLUSION
TA is a rare disease that affects all aspects of QoL in a
negative manner. Most patients with TA will undergo
peripheral vascular surgery during their lifetime. Superior
physical QoL is seen in younger patients and inferior QoL
in those taking immunomodulating medications. To im-
prove both physical and mental QoL, efforts should be
directed to keep disease activity in remission.
We would like to thank John Booros, president of
TARA, for his assistance with this project. More informa-
tion about TARA can be found at www.takayasus.
org/abouttara.htm.
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DISCUSSION
Dr Raphael Adar (Tel-Hashomer, Israel): It is not surprising
that young people with a severe vascular disease have a low quality of
life, or that quality of life improves during disease remission. But is this
disease specific? What were your criteria for diagnosing Takayasu’s
arteritis? These were not mentioned in your presentation.
Dr Abularrage: While it may seem intuitive that quality of life
is poor in this group of patients, to our knowledge, it has not been
examined in a scientific manner prior to this study.
If you look at a lot of the papers in the past few years, there has
been debate on how best to define patients with Takayasu’s arteri-
tis. We surveyed members of the Takayasu’s Arteritis Research
Association with a pre-existing diagnosis of this disease. Further-
more, using diagnostic criteria based on the NIH study of Kerr, et
al., in 1994, we attempted to confirm the diagnosis by asking
questions related to disease activity, method of initial diagnosis,
and symptomatology.
One of the inherent problems with a survey-type question-
naire is that it was not prospective and we did not perform our own
angiography. But in order to gain a national perspective of quality
of life, we accepted those drawbacks to get a larger population
sample.
Dr Adar: Most of your patients were white. Do you have any
information about the ethnic or geographic origins of these pa-
tients?
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Dr Abularrage: No, we do not know the breakdown of the
white population. But one of the things you’ll see is that this was a
US population base and that the distribution of ethnicities is
similar to other US population-based studies for Takayasu’s.
Dr John Ricotta(Stony Brook, NY): Just a suggestion. You
used as a comparator chronic atherosclerotic disease. Perhaps a
better comparison would be some chronic inflammatory diseases
like rheumatoid arthritis or another collagen disease to see how
your Takayasu’s patients compare with some other chronic im-
mune disease.
Dr Abularrage: That’s an excellent point. The reason we
compared the Takayasu’s patients to those with other diseases
associated with peripheral vascular disease was because we were
also interested in the surgical aspect of Takayasu’s, and most
primary vasculitides do not require peripheral vascular interven-
tions. Having said that, we actually did compare the Takayasu’s
patients to patients with systemic lupus erythematosus, rheuma-
toid arthritis, and primary systemas vasculitis; we found that pa-
tients with Takayasu’s have typically scored worse in the SF-36
categories. However, we did not include that data because of a lack
of data reporting in the other studies and an inability to make
meaningful statistical comparisons.
Dr Charles Brantigan (Denver, Colo): My question is a
corollary of the first question that was asked. How do you differ-
entiate Takayasu’s arteritis in your study from other forms of giant
cell arteritis?
Dr Abularrage: All respondents were members of the Taka-
yasu’s Arteritis Research Association with a previous diagnosis of
TA. If anyone responded that they had a second vasculidity in
addition to Takayasu’s arteritis, they were excluded. The study was
blinded as part of our IRB protocol, so we never had access to the
original diagnostic criteria that they underwent. What we did was
we had specific questions in the survey that would allow us to try to
confirm that they had a correct diagnosis by the NIH criteria.
Dr Daniel Clair (Cleveland, Ohio): Did you mention the
number of patients who are on or off steroids? It seems that the
majority, if not all, of these patients would be on steroids and it
probably would be difficult to assess that as an independent vari-
able.
Dr Abularrage: It was mentioned at some point that the
majority are on steroids. But we did look at medication use, and
steroids were not one of the predictors of worsening quality of life,
either physical or mental.
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